Hunter syndrome also called as Mucopolysaccaridosis type II (MPS II), is the disorder affecting several parts of the body. Hunter syndrome is inherited genetic disorder caused by a malfunctioning or missing enzyme. At birth hunter syndrome individuals do not display any features of the disorder, amid ages 2 and 4, changes starts to show as large round cheeks, an enlarged tongue, full lips, and a broad nose. As the disorder advance’s, individuals need more medical assistance. According to the National Institute of Health 2018 report, Frequency of MPS II is 1 in 100,000 to 1 in 160,000 in males. Hunter syndrome is of two type, severe and mild. These both affect many different tissues and organs. Individuals suffering from severe type condition experience a decline in rapid intellectual function and disease progression. Individuals with the severe case begin to lose basic functional skills between at the ages of 6 and 8. The normal life expectancy of these people is 10 to 20 years. Individuals with mild type also have a shortened lifespan, they live into adulthood and their intelligence is not affected, major causes of death in these individuals is airway obstruction and heart disease. Several diagnostic tests are performed to diagnose hunter syndrome, which includes iduronate-2-sulfatase (I2S) enzyme activity test and a genetic testing. The urine test for GAGs is the most frequently used laboratory screening test for an MPS disorder. Advantages offered by this diagnosis test such as quick results and rapid diagnosis is driving growth of the hunter syndrome treatment market globally.
Hunter Syndrome Treatment Market – Dynamics
As Hunter syndrome has no permanent cure, the treatment mainly focuses on management of indications, signs, and difficulties associated with the disease advancement. Increasing number of population suffering from hunter syndrome has boosted the market growth for Hunter syndrome treatments. For instance, in 2014, around 970 patients were enrolled in Hunter Outcome Survey (HOC) which increased to 1195 patients in 2017. Moreover, high burden of rare diseases, tax warier, fee reductions and grants, success for the drugs in pipeline with faster market access, financial incentives for orphan drug development to recover R&D costs, favorable regulations for orphan products development are some of the factors expected to fuel market growth over the forecast period. Rising attention of major biopharmaceutical companies on research and development of drugs for treatment of rare diseases is expected to boost demand for mucopolysaccharidosis treatment drugs. Moreover, the number of treatment options currently in pipeline is expected to boost the growth of market during the forecast period.
However, various issues limiting the market growth are heterogeneity of the disease, high cost of treatment, and lack of awareness are some the factors are restraining the growth of the market.
Hunter Syndrome Treatment Market – Regional Insights
On the basis of region, the global blood stream infection testing market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America accounted for the largest market share in the global hunter syndrome treatment market due to favorable funding for research and development, better medical facilities, regulations for orphan products development, and rising awareness among the people regarding disrobers and disease. For instance, in 2017, Research funded by the National Institute of Neurological Disorders and Stroke (NINDS) has shown that viral-delivered gene therapy can stop the buildup materials stored in the brain cells and improve memory and learning. In the recent years, health insurance coverage and various reimbursement policies for such costly drugs also influencing pharmaceutical companies to invest in drug development. Moreover, Introduction of particular orphan drug regulations has allowed and increased research and development of various therapies for treatment of several such rare diseases. Developing healthcare infrastructure in Asia Pacific region is providing an opportunity for biopharmaceutical companies to penetrate in this region, which is fueling growth of the market.
Hunter Syndrome Treatment Market – Competitive Landscape
Key players operating in the global hunter syndrome treatment market include ArmaGen, Inc., BioMarin Pharmaceutical, Inc., Genzyme, Sangamo Therapeutics, a Sanofi Company, and others. Key players are engaged in developing new technologies and collaborations in order to retain dominant position in the market. For instance, in 2014, Shire Plc announced collaboration with ArmaGen to develop AGT-182 drug for treatment of hunter syndrome.
Hunter Syndrome Treatment Market – Taxonomy
On the basis of treatment type, the global hunter syndrome treatment market is segmented into:
On the basis of end users, global hunter syndrome treatment market is segmented into:
On the basis of geography, global hunter syndrome treatment market is segmented into: